Literature DB >> 1848597

Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction.

S F Lacey1, T Suzutani, K L Powell, D J Purifoy, R W Honess.   

Abstract

We have applied the polymerase chain reaction (PCR) technique to analyse mutations in the thymidine kinase (TK) gene of varicella-zoster virus (VZV) associated with resistance to the 5-bromovinyl (BVaraU) and 5-propynyl (PYaraU) analogues of arabinofuranosyl deoxyuridine. The results from this study allow three clear conclusions to be drawn. Firstly, the technique clearly shows that populations of VZV derived from plaque purification were truly clonal only when the plaques were initiated from cell-free virus (representing a tiny fraction of infectious virus) and plaques initiated by infected cells contained a mixture of variants. Secondly, despite the background mutations caused by errors of the Taq DNA polymerase, mutations relevant to drug resistance can easily be distinguished. The BVaraU-resistant mutant, 7-1, contained an aspartic acid to asparagine mutation at residue 18 and a single base deletion (position 65298 of the VZV DNA sequence), resulting in a frameshift and premature termination of the polypeptide chain, was found in the BVaraU-resistant mutant YSR. PYaraU-resistant virus populations contained viruses with one or more of three independent mutations, i.e. single base substitutions resulting in mutations from leucine to proline at residue 92, histidine to arginine at residue 97 and a deletion of 20bp (residues 65,135 to 65,154). Finally, the technique has uncovered novel sites in the virus TK associated with drug resistance. We conclude that in vitro amplification using the PCR combined with cloning and sequencing is a relatively rapid method for identifying mutations in small virus populations even when they are not homogeneous.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848597     DOI: 10.1099/0022-1317-72-3-623

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Persistent detection of varicella-zoster virus DNA in a previously healthy child after severe chickenpox.

Authors:  Mireille T M Vossen; Mi-Ran Gent; Karla M C Peters; Pauline M E Wertheim-van Dillen; Koert M Dolman; Alex van Breda; René A W van Lier; Taco W Kuijpers
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 2.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

3.  Rapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.

Authors:  T Suzutani; M Saijo; M Nagamine; M Ogasawara; M Azuma
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

5.  Identification of varicella-zoster virus strains by PCR analysis of three repeat elements and a PstI-site-less region.

Authors:  M Takada; T Suzutani; I Yoshida; M Matoba; M Azuma
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.

Authors:  S Koyano; T Suzutani; I Yoshida; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Antiviral activity of oxetanocins against varicella-zoster virus.

Authors:  T Sakuma; M Saijo; T Suzutani; I Yoshida; S Saito; M Kitagawa; S Hasegawa; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.

Authors:  N Ono; S Iwayama; K Suzuki; T Sekiyama; H Nakazawa; T Tsuji; M Okunishi; T Daikoku; Y Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.